These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Alendronate: a bisphosphonate for treatment of osteoporosis. Kirk JK; Spangler JG Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364 [TBL] [Abstract][Full Text] [Related]
7. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. Chailurkit LO; Jongjaroenprasert W; Rungbunnapun S; Ongphiphadhanakul B; Sae-tung S; Rajatanavin R J Bone Miner Metab; 2003; 21(6):421-7. PubMed ID: 14586800 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
10. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885 [TBL] [Abstract][Full Text] [Related]
11. [Long-term insurance for the bones. Effective and safe over 7 years]. MMW Fortschr Med; 2002 Jun; 144(25):52-3. PubMed ID: 12141293 [No Abstract] [Full Text] [Related]
12. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ; N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804 [TBL] [Abstract][Full Text] [Related]
13. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study. Mersereau JE; Khouri C; Jaffe RB Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199 [TBL] [Abstract][Full Text] [Related]
15. Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. Ryan JM; Kelsey P; Ryan BM; Mueller PR Radiology; 1998 Feb; 206(2):389-91. PubMed ID: 9457190 [TBL] [Abstract][Full Text] [Related]
16. Ten years of alendronate treatment for osteoporosis in postmenopausal women. Ruggiero SL; Mehrotra B N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250063 [No Abstract] [Full Text] [Related]
17. Renal function and bisphosphonate safety. Ott SM; Drueke T; Elder G; Fukagawa M; Jorgetti V; Langman CB; Moe S; McCann L; Wang AY; Weisinger J; Wheeler D J Bone Miner Res; 2008 Mar; 23(3):453-4; author reply 455. PubMed ID: 17967135 [No Abstract] [Full Text] [Related]
18. Ten years' experience with alendronate for osteoporosis in postmenopausal women. Bone HG; Hosking D; Devogelaer JP; Tucci JR; Emkey RD; Tonino RP; Rodriguez-Portales JA; Downs RW; Gupta J; Santora AC; Liberman UA; N Engl J Med; 2004 Mar; 350(12):1189-99. PubMed ID: 15028823 [TBL] [Abstract][Full Text] [Related]